🔎 Trials Near Me

መነሻ › አውቶኢሙን ሕመሞች › ኢሊኖይ › Chicago

በChicago፣ IL ለአውቶኢሙን ሕመሞች የሚደረጉ ክሊኒካዊ ጥናቶች

ለአውቶኢሙን ሕመሞች የሚደረጉ 12 ጥናቶች በChicago እና በአካባቢው ባሉ ቦታዎች (በወደ 30 ማይል ውስጥ) ተሳታፊዎችን እየፈለጉ ነው። ማን መሳተፍ እንደሚችል እና የጥናት ቡድኑን እንዴት መገናኘት እንደሚቻል ለማየት ጥናቱን ክፈቱ።

Official study text (English)

ለጥናት ተሳታፊዎችን እየፈለጉ ነው? በዚህ ገጽ ላይ በ$99 ለ30 ቀናት ያስቀምጡት →

A Phase IIa Study of ICG318 CAR-T in Refractory Systemic Lupus Erythematosus With or Without Lupus Nephritis

ተሳታዮችን በመፈለግ ላይደረጃ 2
  • University of Chicago, Chicago
እድሜ ከ16 እስከ 70 · ሁሉም ጾታዎች · የተሻሻለው በ17 ሴፕቴ 2026 · NCT07328581

RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy

ተሳታዮችን በመፈለግ ላይደረጃ 2/3
  • Ann & Robert H. Lurie Children's Hospital of Chicago - Accepting Young Adult and Juvenile Patients, Chicago
  • Northwestern Memorial Hospital - Accepting Adult Patients, Chicago
  • The University of Chicago Medical Center - Accepting Adult and Juvenile Patients, Chicago
እድሜ ከ6 እስከ 75 · ሁሉም ጾታዎች · የተሻሻለው በ17 ሴፕቴ 2026 · NCT06154252

Ublituximab in Autoantibody Positive Immune Mediated Necrotizing Myopathy

ተሳታዮችን በመፈለግ ላይደረጃ 2
  • University of Chicago, Department of Medicine: Rheumatology, Chicago
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ17 ሴፕቴ 2026 · NCT07103746

A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • The University of Chicago Medical Center, Chicago
እድሜ ከ18 እስከ 74 · ሁሉም ጾታዎች · የተሻሻለው በ10 ሴፕቴ 2026 · NCT07085104

RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus

ተሳታዮችን በመፈለግ ላይደረጃ 1/2
  • Northwestern Memorial Hospital, Chicago
  • The University of Chicago Medical Center, Chicago
እድሜ ከ18 እስከ 65 · ሁሉም ጾታዎች · የተሻሻለው በ26 ኦገስ 2026 · NCT06121297

A Study to Investigate Safety and Effectiveness of Porcine Pancreatic Cells (OPF-310) in Patients With Type 1 Diabetes Mellitus

ተሳታዮችን በመፈለግ ላይደረጃ 1/2
  • University of Illinois Hospital & Health Sciences System, Chicago
እድሜ ከ35 እስከ 70 · ሁሉም ጾታዎች · የተሻሻለው በ21 ኦገስ 2026 · NCT06575426

RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis

ተሳታዮችን በመፈለግ ላይደረጃ 2/3
  • Northwestern Memorial Hospital, Chicago
  • The University of Chicago Medical Center, Chicago
እድሜ ከ18 እስከ 75 · ሁሉም ጾታዎች · የተሻሻለው በ17 ኦገስ 2026 · NCT06328777

RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis

ተሳታዮችን በመፈለግ ላይደረጃ 1/2
  • Northwestern Memorial Hospital, Chicago
እድሜ ከ18 እስከ 70 · ሁሉም ጾታዎች · የተሻሻለው በ13 ኦገስ 2026 · NCT06359041

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

ተሳታዮችን በመፈለግ ላይየመመልከት ጥናት
  • Northwestern Memorial Hospital, Chicago
  • Rush University Medical Center, Chicago
  • University of Illinois at Chicago, Chicago
  • እና 2 ተጨማሪ
ለሁሉም እድሜ · ሁሉም ጾታዎች · የተሻሻለው በ6 ጁላይ 2026 · NCT01351545

Study of Single Doses of SBT777101 in Subjects With Rheumatoid Arthritis

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • Northwestern University, Chicago
እድሜ ከ18 እስከ 70 · ሁሉም ጾታዎች · የተሻሻለው በ30 ጁን 2026 · NCT06201416

A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)

ተሳታዮችን በመፈለግ ላይደረጃ 1/2
  • Northwestern University, Chicago
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ29 ሜይ 2026 · NCT04422912

The 1200 Patients Project: Studying the Implementation of Clinical Pharmacogenomic Testing

ተሳታዮችን በመፈለግ ላይየመመልከት ጥናትጤናማ ተሳታዮች ይቀበላሉ
  • University of Chicago Medical Center, Chicago
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ4 ማርች 2026 · NCT01280825

በሌሎች ከተሞች ለአውቶኢሙን ሕመሞች የሚደረጉ ጥናቶች

በChicago ውስጥ ያሉ ሌሎች ጥናቶች

ከ ClinicalTrials.gov የተገኘ መረጃ፣ በ5 ኦክቶ 2026 የተሰብሰቡ። እያንዳንዱ ጥናት የራሱን ቅድመ ሁኔታ ይወስናል፤ የጥናት ቡድኑ ማን መሳተፍ እንደሚችል ይወስናል።